A clinical trial study from the United States found that RPC patients who received preoperative selicrelumab exhibited tumor fibrosis and greater T-cell enrichment, suggesting that neoadjuvant chemotherapy with the CD40 monoclonal antibody selicrelumab altered the tumor microenvironment in resectable pancreatic cancer [33]. Here, CD40 is linked to pancreatic neoplasm.